These conclusions were supported by the results from this study that mβCD, a caveolae disrupting agent, or genetic Cav-1 deficiency in mice impairs microvascular vasodilator function to a greater extent in patients and rodent models of T2D. This evidence concerns the gene CAV1 and type 2 diabetes mellitus.